Sphera Funds Management LTD. purchased a new position in Dova Pharmaceuticals Inc (NASDAQ:DOVA) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 120,000 shares of the company’s stock, valued at approximately $2,516,000. Sphera Funds Management LTD. owned about 0.43% of Dova Pharmaceuticals as of its most recent SEC filing.
A number of other institutional investors have also bought and sold shares of the business. Bank of America Corp DE lifted its stake in Dova Pharmaceuticals by 81.3% in the second quarter. Bank of America Corp DE now owns 5,305 shares of the company’s stock worth $159,000 after purchasing an additional 2,379 shares during the last quarter. Metropolitan Life Insurance Co. NY bought a new stake in Dova Pharmaceuticals in the second quarter worth $128,000. MetLife Investment Advisors LLC bought a new stake in Dova Pharmaceuticals in the second quarter worth $181,000. Stonepine Capital Management LLC purchased a new position in shares of Dova Pharmaceuticals in the third quarter valued at about $145,000. Finally, Commonwealth Equity Services LLC purchased a new position in shares of Dova Pharmaceuticals in the second quarter valued at about $215,000. 37.14% of the stock is owned by institutional investors and hedge funds.
DOVA stock opened at $14.48 on Friday. Dova Pharmaceuticals Inc has a 12-month low of $14.09 and a 12-month high of $37.00. The stock has a market capitalization of $406.70 million, a price-to-earnings ratio of -10.34 and a beta of 0.71. The company has a debt-to-equity ratio of 0.17, a quick ratio of 7.40 and a current ratio of 7.50.
Dova Pharmaceuticals (NASDAQ:DOVA) last released its quarterly earnings data on Thursday, November 8th. The company reported ($0.69) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.12. The firm had revenue of $2.93 million during the quarter, compared to analysts’ expectations of $2.66 million. As a group, equities analysts predict that Dova Pharmaceuticals Inc will post -2.63 EPS for the current year.
A number of equities analysts have issued reports on DOVA shares. Zacks Investment Research upgraded shares of Dova Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, August 15th. BidaskClub upgraded shares of Dova Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, August 24th. Raymond James started coverage on shares of Dova Pharmaceuticals in a research report on Wednesday, August 29th. They issued an “outperform” rating and a $44.00 price objective on the stock. Finally, Leerink Swann decreased their price objective on shares of Dova Pharmaceuticals from $32.00 to $31.00 and set a “market perform” rating on the stock in a research report on Tuesday, September 4th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $33.20.
About Dova Pharmaceuticals
Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead drug candidate is avatrombopag that has completed Phase III clinical trials for the treatment of thrombocytopenia in patients with chronic liver disease.
Further Reading: Why do companies issue stock splits?
Want to see what other hedge funds are holding DOVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dova Pharmaceuticals Inc (NASDAQ:DOVA).
Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.